Skip to content
10-Q

Quarterly Report

NEXIEN BIOPHARMA, INC.

0001493152-24-019400

← back to feed
Filed
May 15, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · May 15, 2024 67.47M sh
Cash And Equivalents Q3 2024 · Mar 31, 2024 $10.07K
Cash And Equivalents Q3 2024 · Jun 30, 2023 $35.15K
Current Liabilities Q3 2024 · Mar 31, 2024 $339.56K
Current Liabilities Q3 2024 · Jun 30, 2023 $295.13K
Total Liabilities Q3 2024 · Mar 31, 2024 $339.56K
Total Liabilities Q3 2024 · Jun 30, 2023 $295.13K
Current Assets Q3 2024 · Mar 31, 2024 $14.27K
Current Assets Q3 2024 · Jun 30, 2023 $43.13K
Total Assets Q3 2024 · Mar 31, 2024 $14.27K
Total Assets Q3 2024 · Jun 30, 2023 $43.13K
Operating Income Q3 2024 · Mar 31, 2024 $11.45M
Shares Diluted Q3 2024 · Mar 31, 2023 62.64M sh
Shares Diluted Q3 2024 · Mar 31, 2023 61.87M sh
Operating Cash Flow Q3 2024 · Mar 31, 2023 −$62.69K
Stockholders Equity Q3 2024 · Mar 31, 2023 −$230.3K
Stockholders Equity Q3 2024 · Dec 31, 2022 −$202.32K
Stockholders Equity Q3 2024 · Sep 30, 2022 −$160.6K
Stockholders Equity Q3 2024 · Jun 30, 2022 −$117.61K
Eps Diluted Q3 2024 · Mar 31, 2023 −$0.00
Eps Diluted Q3 2024 · Mar 31, 2023 −$0.00
Eps Basic Q3 2024 · Mar 31, 2023 −$0.00
Eps Basic Q3 2024 · Mar 31, 2023 −$0.00
Sga Expense Q3 2024 · Mar 31, 2023 $60.62K
Sga Expense Q3 2024 · Mar 31, 2023 $186.54K
Rd Expense Q3 2024 · Mar 31, 2023 $0
Net Income Q3 2024 · Mar 31, 2023 −$79.85K
Net Income Q3 2024 · Mar 31, 2023 −$268.32K
Net Income Q3 2024 · Dec 31, 2022 −$93.59K
Net Income Q3 2024 · Sep 30, 2022 −$94.87K